Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Vascular Transcriptional Remodeling in CABG
NCT05775380Phase 4Recruiting
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in myocardial reperfusion injury comparing Pioglitazone with Placebo/Control (2 arms). Primary endpoint: Change in Sphingosine-1-Phosphate content in HDL at 5 days. Started Jun 2023; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
myocardial reperfusion injury
Beyond the preview
Go deeper on NCT05775380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775380.